Table 1.
Comparison of baseline characteristics of statin users versus non-statin users
| Variables | Statin users
|
Non-statin users | |||
|---|---|---|---|---|---|
| Total | Prior | Continued | New | ||
|
| |||||
| N | 1093 | 268 | 423 | 402 | 1364 |
|
| |||||
| Age (years) mean±SD (median)† | 65.1±13.6 | 70.4±12.5 | 68.2±12.7 | 58.4±12.5 | 60.3±15.0 |
|
| |||||
| Female | 39.7% | 41.0% | 41.6% | 36.8% | 43.1% |
|
| |||||
| Race/ethnicity | |||||
| Black | 29.1% | 27.2% | 23.9% | 35.8% | 35.2% |
| Hispanic | 32.8% | 27.6% | 25.3% | 44.0% | 35.3% |
| White | 38.2% | 45.1% | 50.8% | 20.1% | 29.5% |
|
| |||||
| Risk Factors | |||||
| History of ischemic stroke† | 18.0% | 25.0% | 19.1% | 12.2% | 8.6% |
| History of Diabetes† | 39.2% | 47.0% | 48.0% | 24.9% | 21.5% |
| History of Alzheimer disease | 2.0% | 2.2% | 3.1% | 0.7% | 1.7% |
| History of Dementia (non-Alzheimer) | 5.0% | 11.2% | 5.0% | 1.0% | 3.8% |
| History of hypertension† | 91.0% | 92.2% | 94.8% | 86.3% | 80.4% |
| History of high cholesterol† | 69.7% | 88.1% | 93.6% | 31.8% | 27.3% |
| Prior use of antiplatelet therapy† | 10.9% | 18.3% | 14.2% | 2.5% | 2.7% |
| Prior use of anticoagulants† | 16.7% | 22.8% | 24.8% | 4.2% | 8.4% |
| Prior moderate use of alcohol† | 22.6% | 19.4% | 22.9% | 24.4% | 25.6% |
|
| |||||
| ICH Category‡ | |||||
| Lobar | 33.5% | 43.3% | 38.3% | 21.9% | 29.8% |
| Deep (Includes Primary IVH) | 54.8% | 44.4% | 49.9% | 66.9% | 56.4% |
| Brainstem | 4.1% | 4.1% | 3.3% | 5.0% | 6.5% |
| Cerebellum | 7.6% | 8.2% | 8.5% | 6.2% | 7.3% |
|
| |||||
| Admission GCS (median, IQR) † | 15, 12–15 | 13, 7–15 | 15, 14–15 | 15, 13–15 | 14, 9–15 |
|
| |||||
| Initial Hematoma volume* (mean±SD) | 20.2±26.7 | 39.2±39.6 | 13.7±15.8 | 13.3±15.3 | 21.2±24.0 |
|
| |||||
| Presence of IVH‡ | 40.3% | 54.5% | 36.2% | 35.1% | 46.2% |
|
| |||||
| Microbleed Present | 52.2% | 51.6% | 41.7% | 61.9% | 53.7% |
| Microbleed Location | |||||
| Lobar only | 8.3% | 12.5% | 13.0% | 3.6% | 9.4% |
| Non-Lobar only | 16.6% | 12.5% | 8.1% | 24.0% | 6.5% |
| Lobar plus Non-Lobar | 27.5% | 27.1% | 19.5% | 33.5% | 29.4% |
|
| |||||
| Prestroke mRS† | |||||
| 0 | 65.0% | 52.5% | 61.6% | 76.8% | 74.4% |
| 1 | 14.2% | 15.8% | 16.6% | 10.7% | 9.4% |
| 2 | 12.0% | 16.6% | 12.3% | 8.7% | 7.9% |
| 3 | 5.1% | 9.1% | 5.9% | 1.7% | 4.6% |
| 4 | 3.1% | 5.3% | 2.8% | 2.0% | 2.9% |
| 5 | 0.5% | 0.8% | 0.7% | 0.0% | 0.8% |
*
= CT imaging within 6 hours of onset
†
=P<0.0001 (P-values reflect the comparison between statin users and non-statin users).
‡
=p<0.05 ((P-values reflect the comparison between statin users and non-statin users).